Biophytis and LynxKite Expand Alliance to Accelerate AI-Driven Drug Discovery for Longevity Therapies

The partnership aims to identify and develop Mas receptor activator drug candidates targeting sarcopenia, a degenerative muscle disease associated with aging.

Mar. 13, 2026 at 4:03pm

Got story updates? Submit your updates here. ›

Biophytis SA, a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases, is expanding its partnership with LynxKite Technologies, a leader in advanced analytics and artificial intelligence. The strategic initiative, supported by Singapore's Enterprise Singapore, will integrate AI computational methods into LynxKite's platform to accelerate the discovery of transformative therapies against sarcopenia, a degenerative muscle disease linked to aging.

Why it matters

The collaboration combines Biophytis' expertise in age-related diseases and Mas receptor pharmacology with LynxKite's state-of-the-art AI technologies, chemoinformatics, and software engineering. This partnership aligns with Singapore's Research, Innovation and Enterprise (RIE) 2030 plan, which prioritizes longevity research and development.

The details

The first project, called MASSIVE (MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy), aims to identify and develop Mas receptor (MasR) activator drug candidates targeting sarcopenia. The key objectives include modeling the Mas receptor for structure-based drug design, designing and prioritizing synthetic drug candidates through AI-guided molecule generation, synthesizing and testing promising MasR activators, and selecting and protecting the lead candidate through patent filings.

  • The MASSIVE project was launched in March 2026.

The players

Biophytis SA

A clinical-stage biotechnology company focused on developing drug candidates for age-related diseases, including BIO101 (20-hydroxyecdysone) for muscular diseases and metabolic disorders.

LynxKite Technologies

A leader in advanced analytics and artificial intelligence, known for its flagship open-source platform LynxKite, which has supported over 100 global enterprises in analyzing complex data using graph-based and generative AI approaches.

Enterprise Singapore

A government agency that supports the growth of Singapore-based companies.

Got photos? Submit your photos here. ›

What they’re saying

“The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite's innovative AI to accelerate the discovery of transformative therapies against sarcopenia.”

— Stanislas Veillet, CEO of Biophytis

“We are proud to collaborate with Biophytis on pioneering computational longevity through our LynxKite platfom, which demonstrates how LynxKite can revolutionize discovery by designing, integrating and orchestrating relevant computational tools in diverse modalities.”

— Gyorgy Lajtai, CEO of LynxKite

What’s next

The partners plan to expand the LynxKite-Biophytis collaboration to other modalities beyond the initial MASSIVE project focused on sarcopenia.

The takeaway

This partnership leverages the strengths of Biophytis' expertise in age-related diseases and Mas receptor pharmacology with LynxKite's advanced AI capabilities to accelerate the discovery of innovative longevity therapies, aligning with Singapore's strategic priorities in this field.